×
About 20,684 results

ALLMedicine™ Parkinson Disease Center

Research & Reviews  9,895 results

Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnos...
https://doi.org/10.1212/WNL.0000000000011797
Neurology Chung SJ, Yoo HS et. al.

Mar 3rd, 2021 - To investigate the association between enlarged perivascular spaces (PVSs) in the basal ganglia (BG-PVSs) and long-term motor outcomes in Parkinson's disease (PD). We reviewed the medical records of 248 patients with drug-naïve early-stage PD (fol...

Inverted circadian variation of arterial pressure in a geriatric patient: an indicator ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919995
BMC Geriatrics; Lieten S, Debain A et. al.

Mar 2nd, 2021 - Orthostatic hypotension (OH) in geriatric patients frequently involves a component of autonomic failure (AF). The combination of OH with nocturnal hypertension (NHT) is indicative of AF, which is described as pure (PAF), when neurologic symptoms a...

Identification of LRRK2 Missense Variants in the Accelerating Medicines Partnership Par...
https://doi.org/10.1093/hmg/ddab058
Human Molecular Genetics; Bryant N, Malpeli N et. al.

Feb 28th, 2021 - Pathogenic missense variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified through linkage analysis in familial Parkinson disease (PD). Subsequently, other missense variants with lower effect sizes on PD risk have emerged, ...

Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson di...
https://doi.org/10.1016/j.neulet.2021.135769
Neuroscience Letters; Kakoty V, K C S et. al.

Feb 26th, 2021 - Continual strategies to devise a complete therapeutic cure for neurodegenerative conditions has been a challenge, majorly due to the presence of blood brain barrier. Lack of targeted delivery in order to minimize loss of dopamine (DA) neurones has...

Frequency of Parkinsonism and Parkinson Disease in African Americans in the Chicago Com...
https://doi.org/10.1093/gerona/glab042
The Journals of Gerontology. Series A, Biological Science... Bailey M, Shulman LM et. al.

Feb 25th, 2021 - There is paucity of data about African American (AA) patients with Parkinson's disease (PD) and parkinsonism which may precede PD in older adults. Prior studies suggest that there are lower rates of PD in the AA population, with more cognitive imp...

see more →

Guidelines  155 results

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 6th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon ...

Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials
https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181565
Journal of Parkinson's Disease;

Jul 29th, 2019 - Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri® (ama...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  10,143 results

Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnos...
https://doi.org/10.1212/WNL.0000000000011797
Neurology Chung SJ, Yoo HS et. al.

Mar 3rd, 2021 - To investigate the association between enlarged perivascular spaces (PVSs) in the basal ganglia (BG-PVSs) and long-term motor outcomes in Parkinson's disease (PD). We reviewed the medical records of 248 patients with drug-naïve early-stage PD (fol...

Inverted circadian variation of arterial pressure in a geriatric patient: an indicator ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919995
BMC Geriatrics; Lieten S, Debain A et. al.

Mar 2nd, 2021 - Orthostatic hypotension (OH) in geriatric patients frequently involves a component of autonomic failure (AF). The combination of OH with nocturnal hypertension (NHT) is indicative of AF, which is described as pure (PAF), when neurologic symptoms a...

Identification of LRRK2 Missense Variants in the Accelerating Medicines Partnership Par...
https://doi.org/10.1093/hmg/ddab058
Human Molecular Genetics; Bryant N, Malpeli N et. al.

Feb 28th, 2021 - Pathogenic missense variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified through linkage analysis in familial Parkinson disease (PD). Subsequently, other missense variants with lower effect sizes on PD risk have emerged, ...

Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson di...
https://doi.org/10.1016/j.neulet.2021.135769
Neuroscience Letters; Kakoty V, K C S et. al.

Feb 26th, 2021 - Continual strategies to devise a complete therapeutic cure for neurodegenerative conditions has been a challenge, majorly due to the presence of blood brain barrier. Lack of targeted delivery in order to minimize loss of dopamine (DA) neurones has...

Frequency of Parkinsonism and Parkinson Disease in African Americans in the Chicago Com...
https://doi.org/10.1093/gerona/glab042
The Journals of Gerontology. Series A, Biological Science... Bailey M, Shulman LM et. al.

Feb 25th, 2021 - There is paucity of data about African American (AA) patients with Parkinson's disease (PD) and parkinsonism which may precede PD in older adults. Prior studies suggest that there are lower rates of PD in the AA population, with more cognitive imp...

see more →

News  463 results

A Breakthrough in Parkinson Disease and New Data on Treating Stroke
https://www.medscape.com/viewarticle/933212

Jul 12th, 2020 - This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener, a neurologist from the University of Duisburg-Essen in Germany, presenting six very interesting publications from February 2020 in the fields of stroke, multiple s...

The Gut a New Therapeutic Target for Brain Disorders?
https://www.staging.medscape.com/viewarticle/931719

Jun 3rd, 2020 - Changes in the mucus that lines the gastrointestinal (GI) tract may contribute to bacterial imbalance in the gut and exacerbate core symptoms of autism, Parkinson disease (PD), Alzheimer disease (AD), and multiple sclerosis (MS), new research sugg...

The Gut a New Therapeutic Target for Brain Disorders?
https://www.medscape.com/viewarticle/931719

Jun 3rd, 2020 - Changes in the mucus that lines the gastrointestinal (GI) tract may contribute to bacterial imbalance in the gut and exacerbate core symptoms of autism, Parkinson disease (PD), Alzheimer disease (AD), and multiple sclerosis (MS), new research sugg...

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

see more →

Patient Education  13 results see all →